JYSELECA®▼ (FILGOTINIB) KRIJGT VERGUNNING VOOR DE BEHANDELING VAN VOLWASSEN PATIËNTEN MET MATIGE TOT ERNSTIGE ACTIEVE COLITIS ULCEROSA IN GROOT-BRITTANNIË  

NEXT STORY
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
PREV STORY
PM360 Adds Several New Categories for 2022 Trailblazer Awards
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018

SAN DIEGO and TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) ...

author_avatar
NASDAQ Market News

Merus kündigt Präsentation der klinischen Daten der Phase I für MCLA-158 auf dem „2021 Gastrointestinal Cancers Symposium“ der American Society of Clinical Oncology (ASCO) an

author_avatar
NASDAQ Market News

BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

author_avatar
NASDAQ Market News